HIGHBuilt-inGeographic
100%
United States sales
“10-K Item 1A: 'To date, all of our sales have been to customers in the United States.'”
CBLL · Concentration risk · 10-K extracted
CeriBell (CBLL) concentration risks
Updated
The most significant concentration CeriBell discloses is United States sales at 100%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: CeriBell’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inProduct / Revenue mix
Ceribell System
“10-K Item 1A: 'We expect that revenue from sales of the Ceribell System will continue to account for almost all of our revenue for the foreseeable future.'”
HIGHOutside partySupplier
two primary contract manufacturers in China
“10-K Item 1A: 'We rely on two primary contract manufacturers in China and maintain contractors in China who perform monitoring and quality inspection services.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06CeriBell's concentration risks combine structural, single-product/single-geography exposure with an idiosyncratic supply-chain dependency. To date, all of the company's sales have been to customers in the United States, and the company expects revenue from the Ceribell System to continue accounting for almost all of its revenue for the foreseeable future — both high-band, structural features of a single-product medtech company still early in its commercial life, rather than counterparty risk. The supply side is different in character: CeriBell relies on two primary contract manufacturers in China, along with contractors there for monitoring and quality inspection — a high-band dependency exposure. Unlike the U.S.-revenue and single-product concentrations, which describe what the company is today, the manufacturing dependency is the one line where a disruption — geopolitical, regulatory, or operational — at either Chinese manufacturer could directly constrain product supply and revenue, since there is no disclosed geographic or product diversification to absorb the impact. Investors weighing CeriBell's growth story should treat the single-product, single-market structure as the return driver and the China manufacturing dependency as the key idiosyncratic risk to the supply chain.
For the engine’s reasoning on CBLL’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| CBLL● | CeriBell, Inc. | 3 | 0 | 0 | 3 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.